Thus, while TGFβ generally acts as a potent pro-fibrotic and anti-inflammatory mediator in CAD, the pathophysiological outcome of these actions is highly context-dependent, varying according to the specific cell type, stage of atherosclerosis (early/advanced) and type of lesion (stable/unstable). The gene discussed is TGFB1; the disease is atherosclerosis.